BPC-157: what the research shows, and what it does not

What is BPC-157?

BPC-157, short for Body Protection Compound 157, is a lab-made fragment of a protein found in human gastric juice. It was first characterized in the early 1990s by a research group at the University of Zagreb, which identified a 15 amino acid sequence as the active portion of a much larger stomach protein and began testing it in rat models of gastric injury.

One point worth being precise about: BPC-157 is not a naturally circulating peptide you can be “low” in. It is a synthetic fragment that does not exist in isolated form in human biology. That framing matters when you encounter claims that it “restores” anything.

Proposed mechanisms: what animal research suggests

Three mechanistic stories dominate the literature, and all three come from preclinical work.

Nitric oxide and blood vessel signaling

The most cited pathway involves nitric oxide. A 2020 study in Scientific Reports showed a concentration-dependent vasodilatory effect in isolated rat aorta, traced to the Src, Caveolin-1, and eNOS signaling cascade. Related work links the compound to VEGFR2 activation and increased angiogenesis, the growth of new blood vessels, in animal models of ischemia and wound healing.

Tendon and connective tissue repair

A 2011 study in the Journal of Applied Physiology found dose-dependent activation of the FAK-paxillin pathway in tendon fibroblasts, with faster tendon outgrowth and better cell survival in a rat Achilles model. A string of earlier rat and rabbit studies reported improved healing in tendon, ligament, muscle, and bone injury models.

Gastrointestinal protection

The original research framing was gut protection: the early papers reported reduced gastric and duodenal injury in stressed rats. A clinical program under the designation PL 14736 reached Phase 2 trials in inflammatory bowel disease decades ago but was never completed to approval.

All of this is real research. None of it, so far, tells us what the compound does in a human being.

What the human evidence actually shows

A 2025 systematic review in HSS Journal examined every published study on BPC-157 in the orthopedic and sports medicine literature: 36 studies from 1993 through mid-2024. Thirty-five were animal studies. The single human publication was a retrospective, uncontrolled chart review of 16 patients who received knee injections at one private clinic, with outcomes collected by phone survey and no control group. That review also documented a plasma half-life under 30 minutes in animal pharmacokinetic work, with no published human pharmacokinetic data at all.

A second concern the review made explicit: the overwhelming majority of the literature comes from a single research group. Independent replication, the thing that separates promising findings from durable ones, is thin.

Legal and regulatory status

As of September 2023, the FDA classifies BPC-157 as a Category 2 bulk drug substance on its 503A list, the category for substances that may present significant safety risks. Licensed US compounding pharmacies are prohibited from compounding it. Anything sold as BPC-157 for human use in the US is being sold outside the regulated pharmaceutical system, which means no verified purity, sterility, or potency.

For athletes, the line is even brighter: WADA prohibits BPC-157 at all times under Section S0, unapproved substances, with no therapeutic use exemption available. USADA has published specific guidance warning that it has turned up in wellness products sold outside pharmaceutical channels.

Safety: what is and is not known

Formal animal toxicology, published in 2020, was reassuring within its scope: repeated-dose, genotoxicity, and reproductive studies across four species found no serious toxicity. That is genuinely the best kind of preclinical safety data. It is also still preclinical. No equivalent human safety package exists, and mechanisms the research celebrates cut both ways: a compound proposed to accelerate blood vessel growth raises theoretical concerns, for example around undiagnosed malignancy, that have never been characterized in people.

The biomarkers worth knowing either way

The biology BPC-157 research focuses on, inflammation, tissue repair, and vascular function, is exactly the biology standard comprehensive bloodwork measures. Whether or not an investigational compound is ever part of your future, these baselines make your health legible:

• hs-CRP: the primary marker of systemic inflammation, and the most direct reference point for any anti-inflammatory claim.
• ALT and AST: liver enzymes that establish hepatic baseline before any new compound, supplement, or medication.
• eGFR: kidney filtration, a standard safety reference for anything injectable or unstudied.
• Complete metabolic panel and CBC: organ function, electrolytes, and blood cell indices, the context that makes any future change interpretable.

This is the Insyght premise applied to peptides: measure first, then decide. Every one of these markers is in the Insyght Core Panel, read against optimal ranges rather than just the lab reference range, and reviewed by a physician.

Frequently asked questions

References

Keep reading